# Knee replacement alternatives: what to try and what to ask *Knee replacement alternatives | non-surgical knee treatment queen creek* > Knee replacement alternatives explained plainly, including home care, medicine, regenerative options and surgery. Non-surgical knee treatment queen creek. A sore knee may hurt when you first stand, then settle after several steps. Morning stiffness often comes from joint wear, weak muscles, or an older injury. ## What knee replacement alternatives to try first Regular exercise has the best support for common knee wear. A physical therapist can match the work to your strength and balance. Weight loss can reduce strain when extra pounds add to the load. A cane, brace, or activity change may also make walking easier. Gel used on the knee may be safer than anti-inflammatory tablets for some people. Your doctor can check heart, kidney, and stomach risks before either one. Use these steps steadily for several weeks unless your clinician sets another time. Note walking, stairs, sleep, and swelling so you can judge any change. ## What to ask about clinic treatment QC Kinetix calls its blood-based clinic procedures biologic therapies and regenerative treatments. Medical providers examine the joint and carry out each procedure in the clinic. Staff spin some of your blood until one portion holds extra platelets. That portion is platelet-rich plasma, or PRP; the clinic also lists concentrated PRP. A provider puts the prepared blood material into the sore joint. These procedures don't explain why the knee hurts; the history and exam help do that. Studies disagree about how much PRP helps, and results aren't certain. Ask what happens, what it costs, and when a surgeon's opinion makes more sense. ## When to move the surgery talk forward Surgery deserves more thought when good care hasn't restored enough daily use. Worsening motion and serious joint damage both matter. So does losing the ability to reach the mailbox, use stairs, or sleep well. A replacement may help, but recovery takes work and carries risks. Ask whether the likely gain now outweighs the cost of waiting. If guided exercise hasn't been completed, there may still be useful work left. If exercise and medicine brought no lasting help, watch what walking now requires. When each month brings less movement, another delay may not help. ## Sources 1. The 2019 ACR/Arthritis Foundation guideline makes STRONG recommendations for exercise, weight loss in people with knee and/or hip OA who are overweight or obese, self-efficacy and self-management programs, tai chi, cane use, tibiofemoral bracing for tibiofemoral knee OA, topical NSAIDs for knee OA, oral NSAIDs, and intra-articular glucocorticoid injections for knee OA. Radiofrequency ablation for knee OA, acupuncture, thermal modalities, acetaminophen, duloxetine and tramadol are only CONDITIONAL recommendations. Kolasinski SL, Neogi T, Hochberg MC, et al. — [2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.](https://pubmed.ncbi.nlm.nih.gov/31908163/). *Arthritis & Rheumatology*, 2020. DOI: 10.1002/art.41142. 2. OARSI 2019 designates arthritis education plus structured land-based exercise (with or without dietary weight management) as CORE treatments for knee OA, and education plus structured land-based exercise as core for hip and polyarticular OA. Topical NSAIDs are strongly recommended for knee OA (Level 1A). Intra-articular corticosteroids and hyaluronic acid are Level 1B/2 for knee OA depending on comorbidity and are NOT recommended for hip or polyarticular OA. Oral NSAIDs are not recommended for people with cardiovascular comorbidity or frailty, and oral and transdermal opioids are strongly not recommended (Level 5). Bannuru RR, Osani MC, Vaysbrot EE, et al. — [OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/31278997/). *Osteoarthritis and Cartilage*, 2019. DOI: 10.1016/j.joca.2019.06.011. 3. The Cochrane review of land-based therapeutic exercise for knee osteoarthritis extracted data from 54 randomised trials, assessing pain, physical function and quality of life immediately after treatment and the sustained effect at 2-6 months and beyond 6 months. Only 19 of the included studies (20%) met all three low-risk-of-bias criteria the authors applied. Fransen M, McConnell S, Harmer AR, et al. — [Exercise for osteoarthritis of the knee.](https://pubmed.ncbi.nlm.nih.gov/25569281/). *Cochrane Database of Systematic Reviews*, 2015. DOI: 10.1002/14651858.CD004376.pub3. 4. In 100 adults with mostly moderate-to-severe knee OA who were judged NOT eligible for knee replacement, a 12-week individualised non-surgical programme (neuromuscular exercise, education, insoles, dietary advice, pain medication if indicated) beat usual care at 12 months by 9.6 KOOS4 points (95% CI 4.4 to 14.8), with a number needed to treat of 7.2 for a 15% improvement and no serious treatment-related adverse events. Skou ST, Rasmussen S, Laursen MB, et al. — [The efficacy of 12 weeks non-surgical treatment for patients not eligible for total knee replacement: a randomized controlled trial with 1-year follow-up.](https://pubmed.ncbi.nlm.nih.gov/25937024/). *Osteoarthritis and Cartilage*, 2015. DOI: 10.1016/j.joca.2015.04.021. 5. At 2 years across two parallel randomised trials (200 patients, mean age 66), total knee replacement plus non-surgical treatment beat non-surgical treatment alone by 18.3 KOOS points (95% CI 11.3 to 25.3), and non-surgical treatment in turn beat written advice by 7.0 points (95% CI 0.4 to 13.5). Among patients eligible for replacement, 16 of 50 (32%) in the non-surgical group had surgery within 2 years - meaning two out of three delayed it for at least two years. Skou ST, Roos EM, Laursen MB, et al. — [Total knee replacement and non-surgical treatment of knee osteoarthritis: 2-year outcome from two parallel randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/29723634/). *Osteoarthritis and Cartilage*, 2018. DOI: 10.1016/j.joca.2018.04.014. 6. In a 2-year double-blind randomised trial in 140 patients with symptomatic knee OA (Kellgren-Lawrence grade 2 or 3) and ultrasonic synovitis, intra-articular triamcinolone 40mg every 12 weeks produced significantly greater cartilage volume loss than saline (index-compartment cartilage thickness change -0.21mm vs -0.10mm; between-group difference -0.11mm, 95% CI -0.20 to -0.03) with no significant difference in pain. McAlindon TE, LaValley MP, Harvey WF, et al. — [Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/28510679/). *JAMA*, 2017. DOI: 10.1001/jama.2017.5283. 7. A systematic review and meta-analysis of 169 randomised trials (21,163 participants) of viscosupplementation for knee OA found clear evidence of small-study effects and publication bias. The prespecified main analysis, restricted to 24 large placebo-controlled trials with at least 100 participants per group (8,997 randomised), found a pain reduction of SMD -0.08 (95% CI -0.15 to -0.02) - the confidence interval excluding the prespecified minimal clinically important difference of -0.37. Pereira TV, Jüni P, Saadat P, et al. — [Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/36333100/). *BMJ*, 2022. DOI: 10.1136/bmj-2022-069722. 8. FDA states directly that regenerative medicine therapies - including stem cells, stromal vascular fraction, umbilical cord blood, amniotic fluid, Wharton's jelly, ortho-biologics and exosomes - have NOT been approved for the treatment of any orthopedic condition, naming osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain. FDA further states that being charged for these products, or being offered them outside an FDA-overseen clinical trial, means a patient is likely being deceived and offered a product illegally, and that a product's presence on clinicaltrials.gov or a firm's FDA registration does not mean the product is legally marketed. Reported harms include blindness, tumor formation, neurological events and life-threatening bacterial infections. US Food and Drug Administration, Center for Biologics Evaluation and Research — [Important Patient and Consumer Information About Regenerative Medicine Therapies](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies). *FDA.gov*, 2021. 9. The RESTORE trial randomised 288 community-based participants aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence grade 2 or 3) to three weekly intra-articular injections of leukocyte-poor PRP or saline placebo, with participants, injectors and assessors all blinded. 93% completed the 12-month follow-up. PRP did not produce a clinically meaningful improvement in knee pain over placebo, and did not slow medial tibial cartilage volume loss on MRI. Bennell KL, Paterson KL, Metcalf BR, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. 10. A meta-analysis of 16 randomised trials (807 participants) of intra-articular mesenchymal stem cells for chronic knee pain from osteoarthritis found that at 3-6 months MSC therapy probably produces little to no difference in pain (WMD -0.74cm on a 10cm VAS, 95% CI -1.16 to -0.33, against a minimally important difference of 1.5cm) or physical function, both moderate certainty; at 12 months, probably little to no difference in pain. MSC therapy may increase the risk of any adverse event (RR 2.67, 95% CI 1.19 to 5.99) and of knee pain and swelling (RR 1.58, 95% CI 1.04 to 2.38). Sadeghirad B, Rehman Y, Khosravirad A, et al. — [Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.](https://pubmed.ncbi.nlm.nih.gov/38777213/). *Osteoarthritis and Cartilage*, 2024. DOI: 10.1016/j.joca.2024.04.021. 11. In October 2018 the FTC settled charges that a California physician and two companies he controlled deceptively advertised that 'amniotic stem cell therapy' could treat serious diseases including Parkinson's disease, autism, macular degeneration, cerebral palsy, multiple sclerosis and OSTEOARTHRITIS without competent and reliable scientific evidence. The defendants earned at least USD 3.31 million between 2014 and 2017, with initial injections priced at USD 9,500 to USD 15,000 and follow-up 'booster' treatments at USD 5,000 to USD 8,000. The order imposed a partially suspended USD 3.31 million judgment and required patient notification within 30 days. US Federal Trade Commission, Bureau of Consumer Protection — [FTC Stops Deceptive Health Claims by a Stem Cell Therapy Clinic](https://www.ftc.gov/news-events/news/press-releases/2018/10/ftc-stops-deceptive-health-claims-stem-cell-therapy-clinic). *FTC.gov press release*, 2018. 12. A network meta-analysis of 149 randomised knee-osteoarthritis trials evaluating different placebo types found that intra-articular placebo produced a significant pain effect of its own (effect size 0.29, 95% credible interval 0.09 to 0.49) relative to oral placebo - meaning any uncontrolled injection appears to work partly because it is an injection, and open-label injection results systematically overstate benefit. Bannuru RR, McAlindon TE, Sullivan MC, et al. — [Effectiveness and Implications of Alternative Placebo Treatments: A Systematic Review and Network Meta-analysis of Osteoarthritis Trials.](https://pubmed.ncbi.nlm.nih.gov/26215539/). *Annals of Internal Medicine*, 2015. DOI: 10.7326/M15-0623. 13. In a placebo-controlled trial, 180 patients with knee osteoarthritis were randomised to arthroscopic debridement, arthroscopic lavage or placebo surgery (skin incisions and a simulated procedure without inserting the arthroscope), with patients and outcome assessors blinded. At no point over 24 months did either intervention group report less pain or better function than the placebo group, and the confidence intervals excluded any clinically meaningful difference. Moseley JB, O'Malley K, Petersen NJ, et al. — [A controlled trial of arthroscopic surgery for osteoarthritis of the knee.](https://pubmed.ncbi.nlm.nih.gov/12110735/). *New England Journal of Medicine*, 2002. DOI: 10.1056/NEJMoa013259. 14. A meta-analysis of nine randomised trials of arthroscopic surgery for degenerative knee disease in middle-aged and older patients found a small pain benefit (effect size 0.14, 95% CI 0.03 to 0.26), equal to 2.4mm on a 0-100mm visual analogue scale, present at 3 and 6 months but gone by 24 months, and no significant benefit for physical function (effect size 0.09, 95% CI -0.05 to 0.24). Documented harms included symptomatic deep venous thrombosis (4.13 events per 1,000 procedures, 95% CI 1.78 to 9.60), pulmonary embolism, infection and death. Thorlund JB, Juhl CB, Roos EM, et al. — [Arthroscopic surgery for degenerative knee: systematic review and meta-analysis of benefits and harms.](https://pubmed.ncbi.nlm.nih.gov/26080045/). *BMJ*, 2015. DOI: 10.1136/bmj.h2747. 15. In a randomised sham-controlled trial of genicular artery embolization for mild-to-moderate knee osteoarthritis unresponsive to conservative treatment (58 patients, 29 per arm), pain scores improved substantially in BOTH arms over 12 months (44.44 to 65.61 with GAE; 42.34 to 58.15 with sham), with no significant between-group difference (7.46, 95% CI -13.63 to 28.56, p=0.25) and no significant change in synovitis. The authors concluded the results suggest a sustained placebo effect and do not support clinical implementation of GAE. van Zadelhoff TA, van der Heijden RA, Bierma-Zeinstra SMA, et al. — [Long-term outcomes of genicular artery embolization for knee osteoarthritis: 12-month efficacy and secondary outcomes from a randomized sham-controlled clinical trial.](https://pubmed.ncbi.nlm.nih.gov/42009866/). *European Radiology*, 2026. DOI: 10.1007/s00330-026-12505-8. 16. A systematic review and meta-analysis of eight sham-controlled randomised trials (n=627) of genicular nerve ablation - cooled, monopolar or bipolar radiofrequency ablation, or cryoneurolysis - in adults with knee osteoarthritis INELIGIBLE for arthroplasty found significant pain reduction at 12 weeks versus sham (MD -1.65, 95% CI -2.57 to -0.74, I2=83%) and improved WOMAC function (MD -11.37, 95% CI -18.83 to -3.91, I2=91%), with no serious adverse events reported. Heterogeneity was high and protocols varied. Barreto RB, Barreto AJ, do Nascimento ALM, et al. — [Efficacy and safety of genicular nerve ablation techniques for knee osteoarthritis: a systematic review and meta-analysis of sham-controlled randomized trials.](https://pubmed.ncbi.nlm.nih.gov/41063397/). *Pain Medicine*, 2026. DOI: 10.1093/pm/pnaf140. 17. A Cochrane review of 27 trials (1,767 participants) of intra-articular corticosteroid versus sham or no treatment in knee OA graded the quality of evidence as LOW for all outcomes, citing inconsistent effect estimates, wide variation across trials and imprecise pooled results. Juni P, Hari R, Rutjes AW, et al. — [Intra-articular corticosteroid for knee osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/26490760/). *Cochrane Database of Systematic Reviews*, 2015. DOI: 10.1002/14651858.CD005328.pub3. 18. An individual-participant-data meta-analysis of 621 placebo participants across 10 intra-articular injection trials found placebo response (>=20% pain reduction) was itself predictable: use of local anaesthetic and ultrasound guidance were associated with REDUCED odds of short-term placebo response, and longer trial duration with increased odds at midterm. Any single-arm 'our patients got better' claim about an injection is therefore uninterpretable. Zou K, et al. — [Predictors of Placebo Response to Local (Intra-Articular) Therapy In Osteoarthritis: An Individual Participant Data Meta-Analysis.](https://pubmed.ncbi.nlm.nih.gov/37525486/). *Arthritis Care & Research*, 2024. DOI: 10.1002/acr.25212. ## When to call the clinic or a surgeon The people who own this site also own the Phoenix-area QC Kinetix clinics. Chandler is the nearest office, about 20 to 35 minutes away. There is no charge for the consultation. A clinician examines the joint and reviews the care already tried. The clinician may say a clinic procedure fits the soreness. The answer may instead be that it's time to discuss surgery with a surgeon. For the urgent warning signs described here, don't book a routine consultation. Get assessed the same day. Book a free consultation: --- Plain answers for knee soreness. A plain guide to knee soreness, treatment choices, home steps and surgery timing near Queen Creek. Straight help with knee soreness, daily care, and surgery timing near Queen Creek. This site is operated by the owners of the QC Kinetix Phoenix-area clinics, including the Chandler office named throughout these pages. Read it as first-party: we have a commercial interest in you calling, which is exactly why every claim here is tied to a study you can open yourself. (c) 2026 Knee in Context, Queen Creek, Arizona. Educational content only, and not medical advice for any individual person.